Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time?

@article{Obeid2017ImmunotherapyFH,
  title={Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time?},
  author={Joseph M. Obeid and Paul R. Kunk and Victor M Zaydfudim and Timothy Nj Bullock and Craig L Slingluff and Osama E. Rahma},
  journal={Cancer Immunology, Immunotherapy},
  year={2017},
  volume={67},
  pages={161-174}
}
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and the second most common cause of cancer death worldwide. Current treatment options for patients with intermediate and advanced HCC are limited, and there is an unmet need for novel therapeutic approaches. HCC is an attractive target for immunomodulation therapy, since it arises in an inflammatory milieu due to hepatitis B and C infections and cirrhosis. However, a major barrier to the development and success of… CONTINUE READING
1
Twitter Mention

References

Publications referenced by this paper.
SHOWING 1-10 OF 132 REFERENCES